Our results showed that both FBXO9 knockdown and lenvatinib treatment inhibited tumorigenicity, and knockdown of FBXO9 enhanced the tumor growth inhibition of lenvatinib (Figures 6E–G). This evidence concerns the gene FBXO9 and neoplasm.